INZY – inozyme pharma, inc. (US:NASDAQ)

News

Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Bank of America Co. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com